India's government is considering a 50% price increase for vital cancer drugs cisplatin and carboplatin due to rising raw material costs and potential shortages. The move aims to ensure availability for thousands of patients.
President Donald Trump and Health Secretary Robert F. Kennedy Jr. are defending claims that drug prices were cut by over 100 percent, a statement experts label mathematically impossible. The administration argues these figures reflect the magnitude of previous price hikes.
Regeneron agreed to lower U.S. drug prices for some Americans under a deal with President Trump, part of his 'most favored nation' effort to align U.S. prices with lower international rates. The biotech company will also offer its newly FDA-approved hearing-loss gene therapy Otarmeni for free to eligible patients. The agreements exempt companies from tariffs for three years, including planned up to 100% levies on pharmaceuticals. The FDA approved Otarmeni under its National Priority Voucher program for an ultra-rare genetic condition causing deafness.
Bayer's pharmaceutical head Stefan Oelrich warns that European drug prices must rise to maintain profitability as US policies force companies to lower costs for American consumers, leading to a decline in new drug launches across Europe.
